Results 71 to 80 of about 1,702,455 (203)

Safety, Pharmacokinetics, and Efficacy Study of Porcine and Rabbit Antithymocyte Globulin in the Treatment of Patients With Severe Aplastic Anemia: A Multicenter, Prospective, Randomized, Open‐Label Clinical Trial

MedComm, Volume 7, Issue 11, November 2026.
This prospective trial compared porcine‐ATG and rabbit‐ATG for severe aplastic anemia. Both agents peaked on Day 5, with faster clearance for rabbit‐ATG. Porcine‐ATG induced an early stable neutrophil rise, whereas rabbit‐ATG caused an initial neutrophil drop.
Yawen Zhang, Yingying Zhang, Yuemin Gong, Yu Sun, Guangsheng He   +4 more
wiley   +1 more source

Thrombopoietin receptor agonists: ten years later

Haematologica, 2019
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently used in more than 100 countries.
Waleed Ghanima, Nichola Cooper, Francesco Rodeghiero, Bertrand Godeau, James B. Bussel   +4 more
openaire   +3 more sources

Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage

, 2017
We present here a 63-year old woman with a long history of immune thrombocytopenia. She was hospitalized for a traumatic intracranial hemorrhage with thrombocytopenia.
C. V. Denis, C. Agard, M. Fouassier, O. Espitia, C. Ternisien, P. Boisseau   +5 more
core   +1 more source

His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. [PDF]

, 2015
Ligand binding to the extracellular domain of the thrombopoietin receptor (TpoR) imparts a specific orientation on the receptors' transmembrane (TM) and intracellular domains that is required for physiologic activation via receptor dimerization.
Smith, Steven O, Leroy, Emilie, Sato, Takeshi, Gryshkova, Vitalina, Shwe, Myat Marlar, Dass, Sharmila, Staerk, Judith, Constantinescu, Stefan N., Defour, Jean-Philippe   +8 more
core   +1 more source

Romiplostim as a treatment for immune thrombocytopenia: a review

Journal of Blood Medicine, 2015
Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune ...
Chalmers S, Tarantino MD
doaj  

Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review

Annals of Hematology
Severe aplastic anemia (SAA) is a rare bone marrow failure disorder with high morbidity and mortality, particularly in patients ineligible for hematopoietic stem cell transplantation.
Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Kotb, Haroon Alfadil, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari   +6 more
doaj   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, Volume 209, Issue 5, Page 2223-2232, November 2026.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Junctate is a key element in calcium entry induced by activation of InsP3 receptors and/or calcium store depletion [PDF]

, 2004
In many cell types agonist-receptor activation leads to a rapid and transient release of Ca(2+) from intracellular stores via activation of inositol 1,4,5 trisphosphate (InsP(3)) receptors (InsP(3)Rs).
Arnoult, Christophe, Cristiano Grasso, Treves, Susan, Ronjat, Michel, Mikoshiba, Katsuhiko, ARNOULT C, GRASSO C, TREVES, Susan Nella, Ducreux, Sylvie, DUCREUX S, Smida-Rezgui, Sophia, Franzini-Armstrong, Clara, MIKOSHIBA K, SCHRUM A, Sylvie Ducreux, Susan Treves, RONJAT M, Grasso, Cristiano, Zhu, Michael X., Zorzato, Francesco, SMIDA REZGUI S, Sophia Smida-Rezgui, MOCCAGATTA L, Zhu, Michael, Francesco Zorzato, Clara Franzini-Armstrong, Christophe Arnoult, Luca Moccagatta, Schrum, Adam, Michel Ronjat, ZHU MX, GIRARD T, Girard, Thierry, Katsuhiko Mikoshiba, Thierry Girard, FRANZINI ARMSTRONG C, Moccagatta, Luca, Michael X. Zhu, Adam Schrum, Treves S, Franzini-Armstrong C, Smida-Rezgui S, Zorzato F   +42 more
core   +1 more source

The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]

, 2010
Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core   +4 more sources

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source